ImageneBio, Inc. Deferred Offering Costs
ImageneBio, Inc. (IMA) had Deferred Offering Costs of $0 as of 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:DeferredOfferingCosts · last filed 2026-03-10
- 2025-12-31: Deferred Offering Costs $0.00.
- 2024-12-31: Deferred Offering Costs $1.90M.
- 2021-06-30: Deferred Offering Costs $0.00.
- 2021-03-31: Deferred Offering Costs $0.00.
| Period end | Deferred Offering Costs |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-03-10 |
| 2024-12-31 | $1.90M 10-K · filed 2026-03-10 |
| 2021-06-30 | $0.00 10-Q · filed 2021-08-12 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-13 |
| 2020-12-31 | $500.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |